Increased rates of duodenal mucosal protein synthesis in vivo in patients with untreated coelia disease.
OBJECTIVE
A robust, reproducible method for the measurement of protein synthesis in the gastrointestinal mucosa was applied to investigate possible differences between the rate of duodenal mucosal protein synthesis in coeliac patients and normal control subjects.


METHODS
Eight patients, means (SD) (51 (10) years, 57 (11) kg, 160 (6) cm) with newly diagnosed untreated coeliac disease and seven control subjects (48 (11) years, 71.5 (12) kg, 172 (10) cm) received primed, continuous, intragastric (IG) and intravenous (i.v.) infusions of L-[1-13C]leucine and L-[1-13C]valine after an overnight fast. Distal duodenal biopsy specimens were obtained at endoscopy performed after 240 minutes of infusion. Protein synthesis was calculated from protein labelling relative to intracellular free amino acid enrichment, after appropriate mass spectrometric measurements.


RESULTS
Rates of duodenal protein synthesis were significantly greater in coeliac patients than in control subjects (i.v. tracer, coeliac v control, 3.58 (0.45) v 2.26 (0.22)%/h, p< 0.05; IG tracer, 6.25 (0.97) v 2.34 (0.52)%/h respectively, p < 0.01). The rates of mucosal protein synthesis calculated on the basis of the tracer infused via the intragastric route were higher in patients with coeliac disease than in control subjects. Tissue protein/DNA ratios were significantly reduced in coeliac patients (coeliac v control, 9.2 (1.6) mg/micrograms v 13.0 (2.2) mg/micrograms respectively, p < 0.05) suggesting smaller mucosal cell size in coeliac patients.


CONCLUSIONS
Despite the villous atrophy and reduced cell size observed in coeliac disease, the rates of mucosal protein synthesis are considerably increased. These results suggest that a high rate of protein synthesis may be adaptive to a high rate of protein breakdown or mucosal cell loss in coeliac patients.
Nakshabendi
I M
IM
Department of Gastroenterology, Royal Infirmary, Glasgow.
Downie
S
S
Russell
R I
RI
Rennie
M J
MJ
D000328:Adult; D000601:Amino Acids, Essential / Q000008:administration & dosage; D016022:Case-Control Studies; D002446:Celiac Disease / Q000378:metabolism*; D004247:DNA / Q000032:analysis; D016145:Endoscopy, Digestive System; D005260:Female; D006801:Humans; D007413:Intestinal Mucosa / Q000378:metabolism*; D007651:Keto Acids / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D014176:Protein Biosynthesis; D011506:Proteins / Q000032:analysis; D012313:RNA / Q000032:analysis; D011849:Radioactive Tracers
D000601:Amino Acids, Essential; D007651:Keto Acids; D011506:Proteins; D011849:Radioactive Tracers; D012313:RNA; D004247:DNA